bioRxivCancer Biology
WDR5 represents a therapeutically exploitable target for cancer stem cells in glioblastoma
K. Mitchell, S. Shakya, S. Arora, S. A. Sprowls, D. J. Silver, C. M. Goins, L. Wallace, G. Roversi, R. Schafer, K. Kay, T. E. Miller, A. Lauko, A. Kashyap, J. D. Kass, E. E. Mulkearns-Hubert, S. Johnson, J. Alvarado, J. N. Rich, P. J. Paddison, A. P. Patel, S. R. Stauffer, C. G. Hubert, J. D. Lathia
Abstract
Glioblastomas (GBMs) are heterogeneous, treatment-resistant tumors that are driven by populations of cancer stem cells (CSCs). Despite their importance for tumor growth, few molecular mechanisms critical for CSC population maintenance have been exploited for therapeutic development. We developed a spatially resolved loss-of-function screen in GBM patient-derived organoids to identify essential epigenetic regulators in the SOX2-enriched, therapy resistant niche and identified WDR5 as indispensable for this population. WDR5 is a component of the WRAD complex, which promotes SET1-family-mediated Lys4 methylation of histone H3, associated with positive regulation of transcription. In GBM CSC models, WDR5 inhibitors blocked WRAD complex assembly and reduced H3K4 trimethylation and expression of genes involved in CSC-relevant oncogenic pathways. H3K4me3 peaks lost with WDR5 inhibitor treatment occurred disproportionally on POU transcription factor motifs, including the POU5F1(OCT4)::SOX2 motif. We incorporated a SOX2/OCT4 motif driven GFP reporter system into our CSC cell models and found that WDR5 inhibitor treatment diminished reporter activity. Further, WDR5 inhibitor treatment altered the stem cell state, disrupting CSC in vitro growth and self-renewal as well as in vivo tumor growth. These findings highlight the role of WDR5 and the WRAD complex in maintaining the CSC state and provide a rationale for therapeutic development of WDR5 inhibitors for GBM and other advanced cancers. SignificanceIn this study, we perform an epigenetic-focused functional genomics screen in glioblastoma organoids and identify WDR5 as an essential epigenetic regulator in the SOX2-enriched, therapy resistant cancer stem cell niche. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=135 HEIGHT=200 SRC="FIGDIR/small/461125v2_ufig1.gif" ALT="Figure 1"> View larger version (60K): org.highwire.dtl.DTLVardef@bc5c5eorg.highwire.dtl.DTLVardef@545a2borg.highwire.dtl.DTLVardef@1ebd3c9org.highwire.dtl.DTLVardef@19d5d30_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: organoid / primary culture
- research focus: cancer & tumor microenvironment
- approach: deep learning
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Development and Characterization of Triazole-Based WDR5 Inhibitors for the Treatment of Glioblastoma
Jesse A. Coker, Steven R. Martinez, … Shaun R. Stauffer·JCI InsightPeer-reviewed·May 5, 2026
- CASCADES, a novel SOX2 super-enhancer associated long noncoding RNA, regulates cancer stem cell specification and differentiation in glioblastoma multiforme
U. Shahzad, C. Li, … S. Das·bioRxiv·Sep 5, 2020
- The functional genomic circuitry of human glioblastoma stem cells
Graham MacLeod, Danielle A. Bozek, … Stephane Angers·bioRxiv·Jun 28, 2018
- SUV39H1 Preserves Cancer Stem Cell Chromatin State and Properties in Glioblastoma
Chunying Li, Qiqi Xie, … Jia Shen·JCI InsightPeer-reviewed·Mar 9, 2025
- Identification of Injury-Response State Determinants in Glioblastoma Stem Cells
Fatemeh Molaei, Graham Dickson and Hugh MacLeod, … Stéphane Angers·bioRxiv·Apr 7, 2025
- HAUSP Stabilizes SOX2 through Deubiquitination to Maintain Self-renewal and Tumorigenic Potential of Glioma Stem Cells